Use of calcium channel blockers and Parkinson's disease

American Journal of Epidemiology

Volumn 175, Issue 7, 2012, Pages 627-635

  Pasternak, Björn ^a   Svanström, Henrik ^a   Nielsen, Nete M ^a   Fugger, Lars ^b,c   Melbye, Mads ^a   Hviid, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antihypertensive agents; Calcium channel blockers; Neurology; Parkinson's disease

Indexed keywords

AMILORIDE; AMLODIPINE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; NICARDIPINE; NIFEDIPINE; NILVADIPINE; NITRENDIPINE; THIAZIDE DIURETIC AGENT;

BIOCHEMISTRY; CALCIUM; DISEASE INCIDENCE; DOSE-RESPONSE RELATIONSHIP; DRUG; HEALTH RISK; HYPERTENSION; MENTAL HEALTH; MORTALITY; NERVOUS SYSTEM DISORDER; NEUROLOGY; RISK FACTOR;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; DEMENTIA; DENMARK; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; INCIDENCE; MALE; MORTALITY; PARKINSON DISEASE; PRESCRIPTION; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT DURATION;

AGE FACTORS; AGED; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; DENMARK; DIHYDROPYRIDINES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PARKINSON DISEASE; POISSON DISTRIBUTION; PROPENSITY SCORE; RISK FACTORS;

DENMARK;

EID: 84859509751     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr362     Document Type: Article

References (35)

1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-535. (Pubitemid 44262284)
2. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363(9423):1783-1793. (Pubitemid 38698383)
3. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol. 2003;2(4):229-237. (Pubitemid 37443310)
4. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.N Engl J Med. 2009;361(13):1268-1278.
5. Mattson MP. Calciumand neurodegeneration. Aging Cell. 2007; 6(3):337-350.
6. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol. 2007;6(10):933-938. (Pubitemid 47405004)
7. Kupsch A, Gerlach M, Pupeter SC, et al. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport. 1995; 6(4):621-625.
8. Kupsch A, Sautter J, Schwarz J, et al. 1-Methyl-4-phenyl- 1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 1996; 741(1-2):185-196. (Pubitemid 26426315)
9. Chan CS, Guzman JN, Ilijic E, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature. 2007; 447(7148):1081-1086. (Pubitemid 47014425)
10. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology. 2008;70(16):1438-1444. (Pubitemid 351521937)
11. Ritz B, Rhodes SL, Qian L, et al. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010; 67(5):600-606.
12. Ton TG, Heckbert SR, Longstreth WT Jr, et al. Calcium channel blockers and beta blockers in relation to Parkinson's disease. Parkinsonism Relat Disord. 2007;13(3):165-169. (Pubitemid 46436559)
13. Louis ED, Benito-León J, Bermejo-Pareja F. Antihypertensive agents and risk of Parkinson's disease, essential tremor and dementia: a population-based prospective study (NEDICES). Neuroepidemiology. 2009;33(3):286-292.
14. Simon KC, Gao X, Chen H, et al. Calcium channel blocker use and risk of Parkinson's disease. Mov Disord. 2010;25(12): 1818-1822.
15. Pedersen CB, Gøtzsche H, Møller JO, et al. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53(4):441-449. (Pubitemid 44816920)
16. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011; 39(7 suppl):38-41.
17. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158(9):915-920. (Pubitemid 37323253)
18. Andersen TF, Madsen M, Jørgensen J, et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46(3):263-268. (Pubitemid 29299976)
19. Juel K, Helweg-Larsen K. The Danish registers of causes of death. Dan Med Bull. 1999;46(4):354-357. (Pubitemid 29439149)
20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
21. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130-1139. (Pubitemid 41587600)
22. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology. 2006;66(10 suppl 4):S24-S36.
23. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009;15(3):89-100.
24. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009; 41(12):1303-1307.
25. van der Walt JM, Nicodemus KK, Martin ER, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003;72(4):804-811. (Pubitemid 36403301)
26. Kazuno A, Munakata K, Nagai T, et al. Identification of mitochondrial DNA polymorphisms that alter mitochondrial matrix pH and intracellular calcium dynamics. PLoS Genet. 2006;2(8):e128. (doi:10.1371/journal.pgen.0020128).
27. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304(5674):1158- 1160. (Pubitemid 38661852)
28. Gandhi S, Wood-Kaczmar A, Yao Z, et al. PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell. 2009;33(5):627-638.
29. Mason RP, Leeds PR, Jacob RF, et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem. 1999; 72(4):1448-1456. (Pubitemid 29140815)
30. Simon KC, Chen H, Schwarzschild M, et al. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 2007;69(17):1688-1695. (Pubitemid 350287125)
31. Uchida S, Yamada S, Nagai K, et al. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci. 1997;61(21):2083-2090. (Pubitemid 27478835)
32. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res. 2006;16(1):46-54. (Pubitemid 43237902)
33. de Lau LM, Koudstaal PJ, Hofman A, et al. Subjective complaints precede Parkinson disease: the Rotterdam Study. Arch Neurol. 2006;63(3):362-365.
34. Hernán MA, Takkouche B, Caamaño-Isorna F, et al. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol. 2002;52(3): 276-284. (Pubitemid 35001493)
35. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5): 384-386. (Pubitemid 46184217)